Esophageal Cancer - Pipeline Review, Q1 2011
Global Markets Direct, February 2011, Pages: 128
Esophageal Cancer - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Esophageal Cancer - Pipeline Review, Q1 2011', provides an overview of the Esophageal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Esophageal Cancer. 'Esophageal Cancer - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Esophageal Cancer.
- A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Esophageal Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Esophageal Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Esophageal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Esophageal Cancer
Esophageal Cancer Therapeutics under Development by Companies
Esophageal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Esophageal Cancer Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Shionogi & Co., Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
GenVec, Inc.
Micromet, Inc.
Aphios Corporation
Cell Therapeutics, Inc.
Celldex Therapeutics, Inc.
BTG International Ltd
Sareum Holdings plc
Proteo, Inc.
Supratek Pharma Inc.
GANYMED Pharmaceuticals AG
PharmaEngine, Inc.
PharmaMar, S.A.
ImmunoFrontier, Inc.
Mebiopharm Co., Ltd.
Theradex Systems, Inc.
Kyowa Hakko USA, Inc.
Biotech Pharmaceuticals Co., Ltd.
Universities/Institutes Involved in Esophageal Cancer Therapeutics Development
Esophageal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
CapeOx + Lapatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Herceptin + Xeloda - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tykerb + Capecitabine + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Cetuximab + Cisplatin + Docetaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + 5-Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Capecitabine + Cetuximab + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Capecitabine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Epirubicin + Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cisplatin + fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cisplatin + fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Active Symptom Control - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Nedaplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Oxaliplatin + Capecitabine + Panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Esomeprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Esomeprazole + aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Esomeprazole + Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Cisplatin + Epirubicin Hydrochloride + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FOLFOX regimen + cisplatin + fluorouracil + leucovorin calcium + oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G17DT Immunogen + Cisplatin + Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G17DT Immunogen + Cisplatin + Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iressa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irinotecan hydrochloride trihydrate + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lobaplatin + 5-Fluorouracil + Leucovorin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Navelbine + Cisplatin + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + Tarceva + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trastuzumab + Carboplatin + Paclitaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Esophageal Cancer - Featured News
1. Jul 07, 2010: OPAXIO Phase II Study Results Confirm High Rate Of Complete Response With Low Rate Of Side Effects In Patients With Advanced Esophageal Cancer
2. Jun 07, 2010: OPAXIO Phase II Study Results Confirm High Rate Of Complete Response With Low Rate Of Side Effects In Patients With Advanced Esophageal Cancer
3. Apr 22, 2010: Genentech Submits Supplemental Application To FDA For Herceptin In Advanced HER2-Positive Stomach Cancer
4. Feb 04, 2010: Proteo, Inc./Proteo Biotech AG: Orphan Drug Designation For Elafin In The Treatment Of Oesophagus Carcinoma
5. Nov 16, 2009: Proteo, Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status For Elafin In The Treatment Of Esophagus Carcinoma
6. Oct 01, 2009: Cell Therapeutics, Inc Announced That OPAXIO Produces High Rates Of Pathologic Complete Remission In Patients With Advanced Esophageal Cancer; Study Paves Way For Potential Registration Trial As Radiation Sensitizer
7. Sep 14, 2009: Celldex Therapeutics Announces Dosing Of First Patient In Phase I/II Clinical Trial Of CDX-1401
8. Jun 03, 2009: Paclitaxel Poliglumex (OPAXIO) Added To Cisplatin And Radiation Produces 45% Pathologic Complete Remissions In Patients With Esophageal Cancer
9. Feb 02, 2009: Shionogi announces it has entered into a licensing agreement on Peptide vaccines for cancer treatment with OncoTherapy Science, Inc.
10. Sep 24, 2008: OPAXIO Phase II Trial In Esophageal Cancer To Be Presented In Proffered Session At The International Society Of Gastrointestinal Oncology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Esophageal Cancer, 2011
Products under Development for Esophageal Cancer – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
F. Hoffmann-La Roche Ltd., 2011
Shionogi & Co., Ltd., 2011
Amgen Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
GenVec, Inc., 2011
Micromet, Inc., 2011
Aphios Corporation, 2011
Cell Therapeutics, Inc., 2011
Celldex Therapeutics, Inc., 2011
BTG International Ltd, 2011
Sareum Holdings plc, 2011
Proteo, Inc., 2011
Supratek Pharma Inc., 2011
GANYMED Pharmaceuticals AG, 2011
PharmaEngine, Inc., 2011
PharmaMar, S.A., 2011
ImmunoFrontier, Inc., 2011
Mebiopharm Co., Ltd., 2011
Theradex Systems, Inc., 2011
Kyowa Hakko USA, Inc., 2011
Biotech Pharmaceuticals Co., Ltd., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products
List of Figures
Number of Products under Development for Esophageal Cancer, 2011
Products under Development for Esophageal Cancer – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
